RCS - Tiziana Life Science - Information Regarding Migration of UK Shares
23/12/2021 16:40
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20211223:nRSW6795Wa&default-theme=true
RNS Number : 6795W Tiziana Life Sciences PLC 23 December 2021
Information For Shareholders Regarding Migration of UK Shares
London, 23 December 2021 - Tiziana Life Sciences(Nasdaq: TLSA) a biotechnology
company focused on innovative therapeutics for oncology, inflammation, and
infectious diseases has added some additional information on its website for
shareholders regarding the migration of its UK shares.
The information can be found at: https://ir.tizianalifesciences.com/faqs
(https://ir.tizianalifesciences.com/faqs)
For further information please contact:
Keeren Shah, Finance Director: +44 (0) 207 495 2379 or
email: info@tizianalifesciences.com (mailto:info@tizianalifesciences.com)
About Tiziana Life Sciences
Tiziana Life Sciences plc is a dual listed (NASDAQ: TLSA & UK LSE: TILS)
biotechnology company that focuses on the discovery and development of novel
molecules to treat human diseases in oncology, inflammation and infectious
diseases. In addition to Milciclib, the Company will be shortly initiating
Phase 2 studies with orally administered Foralumab for Crohn's Disease and
nasally administered Foralumab for progressive multiple sclerosis. Foralumab
is the only fully human anti-CD3 monoclonal antibody ("mAb") in clinical
development in the world. This Phase 2 compound has potential application in a
wide range of autoimmune and inflammatory diseases, such as Crohn's Disease,
multiple sclerosis, type-1 diabetes ("T1D"), inflammatory bowel disease
("IBD"), psoriasis and rheumatoid arthritis, where modulation of a T-cell
response is desirable. The Company is accelerating development of
anti-Interleukin 6 receptor ("IL6R") mAb, a fully human monoclonal antibody
for treatment of IL6-induced inflammation, especially for treatment of
COVID-19 patients.
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END NRAFLFVEFVLVFIL